{Reference Type}: Journal Article
{Title}: Efficacy of infliximab, abatacept, and cenicriviroc for the treatment of adults hospitalized with COVID-19 pneumonia.
{Author}: Lin DY;Wang J;Anstrom KJ;LaVange LM;Wen J;Bozzette SA;Powderly WG; ;
{Journal}: Int J Infect Dis
{Volume}: 146
{Issue}: 0
{Year}: 2024 Sep 7
{Factor}: 12.074
{DOI}: 10.1016/j.ijid.2024.107168
{Abstract}: A randomized, double-blind, placebo-controlled clinical trial was conducted to investigate the efficacy of infliximab, abatacept, and cenicriviroc in treating patients hospitalized with COVID-19. The patient's clinical status was assessed daily on an 8-point ordinal scale. We evaluated the totality of evidence on the efficacy of the 3 immunomodulators by considering all possible changes in the clinical status of each patient over time. We demonstrated that infliximab accelerated improvement and reduced deterioration of clinical status when added to standard of care. There was also evidence for the benefit of abatacept. There was no evidence for the benefit of cenicriviroc.